Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MedImmune Halves FluMist Price To $23.50; Taps Henry Schein As Distributor

This article was originally published in The Pink Sheet Daily

Executive Summary

The company had indicated a price reduction was under consideration based on weak sales during FluMist's first year on the market. In addition to selling FluMist, Henry Schein will also help promote the product to primary care physicians.

You may also be interested in...



MedImmune Takes Back FluMist: Physician Education, Not DTC, Will Be Near-Term Focus

MedImmune will add 55 commercial positions to help compensate for the loss of the Wyeth partnership. MedImmune will pay Wyeth $25 mil. plus future royalties and milestones under dissolution agreement.

Wyeth Drops MedImmune FluMist Partnership, Will Transfer Clinical Data

MedImmune will continue developing the flu vaccine without a partner. The company has signaled that Wyeth might pull out of the partnership as a result of lower than expected revenues for the product.

FluMist Price Will Likely Be Cut To $20-$25 Per Dose, MedImmune Says

One factor holding up final price is ongoing discussions as to whether Wyeth will remain in the FluMist partnership. Of the 900,000 doses sold during the 2003/2004 season, about 50% were returned, MedImmune reported.

Topics

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel